425

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 13, 2005

Date of Report (Date of earliest event reported)

Medicis Pharmaceutical Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State of Incorporation) 0-18443
(Commission File Number) 52-1574808
(IRS Employer
Identification Number)

8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)

(602) 808-8800
(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 1.01 Entry into a Material Definitive Agreement.
	Item 1.02 Termination of a Material Definitive Agreement.
	Item 8.01 Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Exhibit 10.1
Exhibit 99.1

Item 1.01 Entry into a Material Definitive Agreement.

     On December 13, 2005, Medicis Pharmaceutical Corporation (“Medicis”) announced the execution of a Merger Termination Agreement (the “Termination Agreement”) between Medicis, Masterpiece Acquisition Corp., a wholly-owned subsidiary of Medicis, and Inamed Corporation (“Inamed”). Pursuant to the Termination Agreement, the parties agreed to terminate the Agreement and Plan of Merger, dated as of March 20, 2005, by and among Medicis, Masterpiece Acquisition Corp. and Inamed (the “Merger Agreement”) effective upon execution of the Termination Agreement and Medicis’ receipt of a termination payment from Inamed in the amount of $90,000,000 and reimbursement of certain expenses. As a result of the termination of the Merger Agreement, the pending merger between Medicis and Inamed has been terminated.

     The foregoing description of the Termination Agreement is qualified in its entirety by reference to the Termination Agreement and the press release attached as Exhibits 10.1 and 99.1, respectively, and incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement.

     The disclosure set forth in Item 1.01 of the Current Report is incorporated by reference herein.

Item 8.01 Other Events.

     Medicis also announced that, as a result of the termination of the Merger Agreement, Medicis stockholders will not vote upon the following proposals at the annual meeting of Medicis stockholders to be held on December 19, 2005:

• The proposal to approve the issuance of shares of Medicis Class A common stock pursuant to the Merger Agreement.

• The proposal to approve an amendment to Medicis’ certificate of incorporation to increase the number of authorized shares of Medicis Class A common stock from 150,000,000 to 300,000,000 and change Medicis’ name from “Medicis Pharmaceutical Corporation” to “Medicis”.

Item 9.01 Financial Statements and Exhibits.

(c)

10.1	Merger Termination Agreement, dated as of December 13, 2005, by and among Medicis Pharmaceutical Corporation, a Delaware corporation, Masterpiece Acquisition Corp., a Delaware corporation, and Inamed Corporation, a Delaware corporation.
99.1	Press release, dated December 13, 2005.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 13, 2005	By:	/s/ Mark A. Prygocki, Sr.
		Mark A. Prygocki, Sr.
		Executive Vice President, Chief Financial Officer, Corporate Secretary and Treasurer

EX-10.1

                                                                    EXHIBIT 10.1

                          MERGER TERMINATION AGREEMENT

      This Merger Termination Agreement (this "Agreement") is entered into as of
December 13, 2005 by and among Medicis Pharmaceutical Corporation, a Delaware
corporation ("Parent"), Masterpiece Acquisition Corp., a Delaware corporation
and a wholly owned subsidiary of Parent ("Merger Sub"), and Inamed Corporation,
a Delaware corporation (the "Company").

                                    RECITALS

      WHEREAS, Parent, Merger Sub and the Company have entered into an Agreement
and Plan of Merger dated as of March 20, 2005 (the "Merger Agreement")
(capitalized terms used but not otherwise defined herein shall have the
respective meanings provided for such terms in the Merger Agreement); and

      WHEREAS, Parent, Merger Sub and the Company desire to terminate the Merger
Agreement as provided herein effective immediately upon execution of this
Agreement and Medicis' receipt of the Company Termination Fee and Reimbursement
Fees pursuant to Section 1(b) hereof.

                                    AGREEMENT

      NOW, THEREFORE, in consideration of the premises and the agreements set
forth herein, and intending to be legally bound hereby, the parties agree as
follows:

      1.    Termination of Merger Agreement.

            (a) Parent, Merger Sub and the Company hereby terminate the Merger
Agreement pursuant to Section 7.01 of the Merger Agreement, effective
immediately upon the execution of this Agreement and Medicis' receipt of the
Company Termination Fee and Reimbursement Fees pursuant to Section 1(b) hereof.

            (b) The Company shall pay to Parent (i) the Company Termination Fee
of $90,000,000 and (ii) $481,985 pursuant to Section 5.10(a) of the Merger
Agreement (the "Reimbursement Fees"), concurrently with the execution of this
Agreement. Payment of the Company Termination Fee and the Reimbursement Fees by
the Company shall be made by wire transfer of immediately available funds to the
account designated on Schedule 1 hereto. Parent and Merger Sub agree and
acknowledge that payment of the Termination Fee and the Reimbursement Fees shall
constitute full and final satisfaction of any and all obligations of the Company
under Section 5.10 of the Merger Agreement.

      2.    Effect of Termination; Mutual Discharge and Release.

            Each party hereto, on behalf of itself and, to the extent permitted
by law, its affiliates, subsidiaries, directors, officers, stockholders,
employees, agents, financial and legal advisors and other Representatives, and
the successors and assigns of each of them (each, a "Releasing Party"), hereby
fully, finally and forever releases each other party hereto and each of their
respective affiliates, subsidiaries, directors, officers, stockholders,
employees, agents, financial

and legal advisors and other representatives, and the successors and assigns of
each of them, from any and all liabilities and obligations, claims, causes of
action and suits, at law or in equity, whether now known or unknown, based on or
arising out of facts of which such party has Knowledge (as defined below) on or
prior to the date hereof, whether arising under any United States federal, state
or local or any foreign law or otherwise, that any Releasing Party has or has
had arising out of, relating to, or in connection with the Merger Agreement and
the transactions contemplated thereby, including, without limitation, any
liability or obligation arising out of any breach based on facts of which such
party has Knowledge on or before the date hereof of any representation,
warranty, covenant or agreement contained in the Merger Agreement, provided that
nothing in this Section 2 shall impair the survival and full force of the terms
of the Confidentiality Agreement or Parent's right to receive immediate payment
of the Company Termination Fee and the Reimbursement Fees pursuant to Section 1
hereof and Section 5.10 of the Merger Agreement.

      3.    Survival of Confidentiality Agreement.

            (a) Notwithstanding anything contained in this Agreement to the
contrary, the provisions of the Confidentiality Agreement dated as of November
17, 2004 between Parent and the Company (the "Confidentiality Agreement") shall
survive and remain in full force and effect in accordance with their terms.

            (b) Each of Parent and Merger Sub, on the one hand, and the Company,
on the other hand, shall promptly deliver to the other all Proprietary
Information of the other party, and, at the other party's sole election, return
or destroy (provided that any such destruction shall be certified by a duly
authorized Representative of the party) all copies, reproductions, summaries,
analyses or extracts thereof or based thereon (whether in hard-copy form or on
intangible media, such as electronic mail or computer files) in the party's
possession or in the possession of any of its Representatives; provided, that if
a legal proceeding has been instituted to seek disclosure of the Proprietary
Information, such material shall not be destroyed until the proceeding is
settled or a final judgment with respect thereto has been rendered; and
provided, further, that all documents reflecting the party's final evaluation of
the Merger Agreement and the reasons for its decision to proceed or not to
proceed with the transactions contemplated thereby will not be required to be
returned or destroyed, however, the Confidentiality Agreement will continue to
apply to any such information on the terms set forth herein. Notwithstanding the
return or destruction of any Proprietary Information, or documents or material
containing or reflecting any Proprietary Information, the parties will continue
to be bound by their obligations of confidentiality and other obligations
hereunder for the term of the Confidentiality Agreement (or such other term as
may be applicable to the specific obligation).

      4. Representations and Warranties of Parent and Merger Sub. Parent and
Merger Sub hereby represent to the Company as follows: Each of Parent and Merger
Sub has full corporate power and authority to execute, deliver and perform this
Agreement; this Agreement has been duly and validly authorized by their
respective boards of directors and executed and delivered by each of them, and
constitutes a valid binding obligation of each of them, enforceable against each
of them in accordance with its terms, except as such enforceability may be
limited by bankruptcy, insolvency, fraudulent conveyance reorganization,
moratorium or other similar laws now or hereafter in effect relating to
creditors' rights generally and by general equitable principles; and neither
Parent nor Merger Sub have assigned, transferred or conveyed to any other Person
any claim


                                       2

or any portion thereof or interest therein relating to any of the matters that
are the subject of this Agreement.

      5. Representations and Warranties of the Company. The Company hereby
represents to Parent as follows: The Company has full corporate power and
authority to execute, deliver and perform this Agreement; this Agreement has
been duly and validly authorized by the Company's board of directors and
executed and delivered by the Company, and constitutes a valid binding
obligation of the Company, enforceable against the Company in accordance with
its terms, except as such enforceability may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other similar
laws now or hereafter in effect relating to creditors' rights generally and by
general equitable principles; the Company has available and ready funds
sufficient to pay the amounts set forth in Section 1 hereof; and the Company has
not assigned, transferred or conveyed to any other Person any claim or any
portion thereof or interest therein relating to any of the matters that are the
subject of this Agreement.

      6. Public Announcement. Parent and the Company acknowledge that each
intends to issue a press release promptly after the date of this Agreement with
respect to this Agreement and the termination of the Merger Agreement. Each of
Parent and the Company shall use reasonable efforts to consult with the other
before issuing such press release, and in no event may either party issue such
press until the termination of the Merger Agreement has become effective
pursuant to Section 1 hereof.

      7.    Governing Law; Waiver of Jury Trial.

            (a) This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to the conflict of
law provisions thereof. This Agreement shall be binding upon any successor to
the Company or Parent or Merger Sub. In addition, each of the parties hereto (a)
irrevocably and unconditionally consents to submit itself to the jurisdiction of
the Court of Chancery of the State of Delaware in the event any dispute arises
out of this Agreement or the transactions contemplated by this Agreement, (b)
agrees that it will not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court, (c) agrees that it will
not bring any action relating to this Agreement or the transactions contemplated
by this Agreement in any court other than the Court of Chancery of the State of
Delaware, and each of the parties irrevocably waives the right to trial by jury,
(d) waives, to the fullest extent permitted by law, the defense of an
inconvenient forum to the maintenance of such action on the Court of Chancery of
the State of Delaware, and (e) irrevocably consents to service of process by
first class certified mail, return receipt requested, postage prepaid, to the
address at which such party is to receive notice.

            (b) Each of the parties hereto hereby waives to the fullest extent
permitted by applicable law any right it may have to a trial by jury with
respect to any litigation directly or indirectly arising out of, under or in
connection with this Agreement or the Merger Agreement.

      8. Specific Performance. The parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement were not performed in
accordance with the terms hereof and that the parties shall be entitled to
specific performance of the terms hereof, in addition to any other remedy at law
or in equity. It is accordingly agreed that in any proceeding seeking specific
performance each of the parties will waive the defense of adequacy of a remedy
at law.


                                       3

      9.    Miscellaneous.

            (a) The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect in any way the
meaning or interpretation of this Agreement.

            (b) Each party agrees to use reasonable effort to take reasonable
actions as any other party may reasonably request to carry out the intent of
this Agreement and to take any other actions required under applicable Law to
carry out and effectuate the intent of this Agreement.

            (c) This Agreement, the Merger Agreement and the Confidentiality
Agreement constitute the entire agreement among the parties hereto with respect
to the subject matter hereof and supersede all prior agreements, understandings
and negotiations, both written and oral, between the parties with respect to the
subject matter of this Agreement. No representation, inducement, promise,
understanding, condition or warranty not set forth herein has been made or
relied upon by either party hereto in connection with this Agreement.

            (d) This Agreement may be modified or amended only by a writing
signed by the parties hereto. This Agreement may be executed and delivered
(including by facsimile transmission) in one of more counterparts, and by the
different parties hereto in separate counterparts, each of which when executed
and delivered shall be deemed to be an original but all of which taken together
shall constitute one and the same agreement.

            (e) If any provision of this Agreement is held to be illegal,
invalid or unenforceable under any present or future laws, and if the rights or
obligations of any party hereto under this Agreement will not be materially and
adversely affected thereby, (a) such provision will be fully severable, (b) this
Agreement will be construed and enforced as if such illegal, invalid or
unenforceable provisions had never comprised a part hereof, and (c) the
remaining provisions of this Agreement will remain in full force and effect and
will not be affected by the illegal, invalid or unenforceable provision or by
its severance herefrom.

            (f) If any legal action, including, without limitation, an action
for arbitration or injunctive relief, is brought relating to this Agreement or
the Merger Agreement or the breach or alleged breach hereof or thereof, the
prevailing party in any final judgment or arbitration award, or the
non-dismissing party in the event of a voluntary dismissal by the party
instituting the action, shall be entitled to the full amount of all reasonable
legal expenses, including all court costs, arbitration fees and actual
attorneys' fees paid or incurred in good faith.

            (g) A party hereto shall be deemed to have "Knowledge" of a
particular fact or other matter, and a particular fact or other matter shall be
deemed "known to" a party hereto if any executive officer of such party (a) is
actually aware of such fact or matter, or (b) would be expected to discover or
otherwise become aware of such fact or other matter after consultation with its
outside legal advisors.


                                       4

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their respective authorized officers as of the day and year
first above written.

                        MEDICIS PHARMACEUTICAL CORPORATION



                         By: /s/ Mark A. Prygocki, Sr.
                             ---------------------------------------------------
                             Name:   Mark A. Prygocki, Sr.
                             Title:  Executive Vice President, Chief Financial
                                     Officers, Corporate Secretary and Treasurer


                         MASTERPIECE ACQUISITION CORP.



                         By: /s/ Mark A. Prygocki, Sr.
                             ---------------------------------------------------
                             Name:   Mark A. Prygocki, Sr.
                             Title:  Vice President, Secretary and Chief
                                     Financial Officer


                         INAMED CORPORATION



                         By: /s/ Nicholas Teti
                             ---------------------------------------------------
                             Name:  Nicholas Teti
                             Title: Chairman, President and Chief Executive
                                    Officer



                                       5

EX-99.1

Exhibit 99.1

Medicis Terminates Merger Agreement with Inamed and Receives $90 Million Termination Fee

SCOTTSDALE, Ariz.—(BUSINESS WIRE)—Dec. 13, 2005—Medicis (NYSE:MRX — News; the “Company”) today announced that it has elected to terminate its merger agreement with Inamed Corporation (NASDAQ:IMDC — News), and has received a termination fee payment of $90 million from Inamed. Medicis and Inamed originally entered the merger agreement on March 20, 2005.

“After careful evaluation by the Board of Directors with consultation from outside counsel and financial advisors, we have concluded that it is in the best interests of Medicis shareholders not to raise our offer for Inamed,” said Jonah Shacknai, Chairman and Chief Executive Officer of Medicis. “We are very excited about our business prospects, and have energized our corporate development efforts in both the aesthetic and dermatology sectors. Our pipeline is rich in near- and long-term opportunities.”

Medicis will hold its annual meeting of stockholders as previously scheduled on December 19, 2005, to elect directors and ratify the selection of its independent auditors. Proposals one and two in the Notice of Annual Meeting of Stockholders, relating specifically to the issuance of additional shares pursuant to the merger agreement and an amendment to the certificate of incorporation to increase the number of authorized shares and to change the name of the Company from “Medicis Pharmaceutical Corporation” to “Medicis,” will not be voted on at the meeting due to the termination of the merger agreement.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin and skin-structure infections. The Company’s products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.

The Company’s products include the prescription brands RESTYLANE®, DYNACIN® (minocycline HCl), LOPROX® (ciclopirox), OMNICEF® (cefdinir), PLEXION® (sodium sulfacetamide/sulfur), TRIAZ® (benzoyl peroxide), LIDEX® (fluocinonide) Cream, 0.05%, VANOS™ (fluocinonide) Cream, 0.1%, and SYNALAR® (fluocinolone acetonide), BUPHENYL® (sodium phenylbutyrate) and AMMONUL® (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea Cycle Disorder, and the over-the-counter brand ESOTERICA®.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements, including Medicis’ future prospects, business development activities and product pipeline and Medicis’ intention to hold its annual meeting on December 19, 2005. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis.

The Company’s business is subject to all risk factors outlined in the Company’s most recent annual report on Form 10-K and other documents we file with the Securities and Exchange Commission. At the time of this press release, the Company cannot, among other things, assess the likelihood, timing or forthcoming results of research and development projects and the risks associated with the FDA approval process, risks associated

with significant competition within the Company’s industry, nor can the Company validate its assumptions of the full impact on its business of the approval of competitive generic versions of the Company’s core brands, in particular, the recent approval of a generic LOPROX® Cream and LOPROX® TS, or a substitutable DYNACIN® Tablet form, and any future competitive product approvals that may affect the Company’s brands. Additionally, Medicis may acquire and/or license products or technologies from third parties to enter into new strategic markets. The Company periodically makes up-front, non-refundable payments to third parties for research and development work which has been completed and periodically makes additional non-refundable payments for the achievement of various milestones. There can be no certainty in which periods these potential payments could be made, nor if any payments such as these will be made at all. Any estimated future guidance does not include the potential payments associated with any such transactions. Also, there are a number of additional important factors that could cause actual results to differ materially from those projected, including the anticipated size of the markets for Medicis’ products, the availability of product supply and the receipt of required regulatory approvals; the risks and uncertainties normally incident to the pharmaceutical and medical device industries including product liability claims, the introduction of federal and/or state regulations relating to the Company’s business, dependence on sales of key products, the uncertainty of future financial results and fluctuations in operating results, dependence on Medicis’ strategy including the uncertainty of license payments and/or other payments due from third parties, the timing and success of new product development by Medicis or third parties, competitive product introductions, the risks of pending and future litigation or government investigations and other risks described from time to time in Medicis’ SEC filings including its Annual Report on Form 10-K for the year ended June 30, 2005, and other documents we file with the Securities and Exchange Commission. Additionally, there can be no assurance as to when or if any of the holders of the Notes will have the right to convert or if the Notes will be converted. Forward-looking statements represent the judgment of Medicis’ management as of the date of this release, and Medicis disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company. OMNICEF® is a registered trademark of Abbott Laboratories, Inc. under a license from Fujisawa Pharmaceutical Co., Ltd. RESTYLANE® is a registered trademark of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation. All other marks (or brands) and names are the property of Medicis or its Affiliates.